Press Releases

Year

May 30, 2019

Osmotica Pharmaceuticals plc to Present at Jefferies 2019 Global Healthcare Conference

BRIDGEWATER, N.J. , May 30, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Brian Markison , Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn

May 14, 2019

Osmotica Pharmaceuticals plc to Present at 2019 RBC Capital Markets Global Healthcare Conference

BRIDGEWATER, N.J. , May 14, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Brian Markison , Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn

May 9, 2019

Osmotica Pharmaceuticals plc Reports First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress

First quarter 2019 total revenue of $57.1 million ; net loss of $6.2 million Positive topline results from second Phase III clinical trials of RVL-1201 for ptosis or droopy eyelid BRIDGEWATER, N.J. , May 09, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”)

May 6, 2019

Osmotica Pharmaceuticals plc Announces Positive Topline Results of Phase III Clinical Trials of RVL-1201 (“RVL”) for Acquired Blepharoptosis (ptosis or droopy eyelid)

- Second Phase III Study 202 Meets Primary Endpoint; Provides Additional Evidence of Efficacy and Safety - - Long-term Phase III Study 203 Provides Additional Evidence of Safety - - Company to Host Conference Call on Tuesday, May 7 th at 12pm ET with Dr. Chuck Slonim and Dr.

May 2, 2019

Osmotica Pharmaceuticals plc to Provide First Quarter 2019 Business and Financial Update on May 9, 2019

BRIDGEWATER, N.J. , May 02, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release its 2019 first quarter financial results on Thursday, May 9, 2019 , after the

March 27, 2019

Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress

Reported fourth quarter and full year 2018 total revenue of $65.7 million and $263.7 million , respectively Completed and reported preliminary topline results from second Phase III study of arbaclofen extended-release (ER) tablets for the treatment of spasticity associated with Multiple Sclerosis

March 21, 2019

Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2018 Business and Financial Update on March 27, 2019

BRIDGEWATER, N.J. , March 21, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release its 2018 fourth quarter and full year financial results on Wednesday, March

Investor Relations

News

Press Releases

Press Releases

Press Releases